Article
Gastroenterology & Hepatology
Jihyun An, Seungbong Han, Ha Il Kim, Ju Hyun Shim
Summary: This study compared different treatment options for advanced hepatocellular carcinoma and found that atezolizumab+bevacizumab was the best first-line systemic modality, especially for patients with portal invasion.
HEPATOLOGY COMMUNICATIONS
(2022)
Article
Ophthalmology
G. H. Chen, R. Tzekov, S. H. Mao, Y. H. Tong, F. Z. Jiang, W. S. Li
Summary: Intravitreal conbercept (IVC) in pars plana vitrectomy (PPV) for patients with proliferative diabetic retinopathy (PDR) has shown to be effective in reducing intraoperative bleeding, shortening surgical time, and improving postoperative outcomes.
Article
Immunology
Xin Zhang, Yaping Jiang, Qiangqiang Fu, Xiaoyan Zhang, Yihui Chen
Summary: This meta-analysis found that bevacizumab significantly reduced the recurrence rate of pterygium after surgery, and did not differ in terms of complication risk compared to control treatments.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Virology
Fangyuan Tian, Zhaoyan Chen, Qiyi Feng
Summary: This study aimed to evaluate the efficacy and safety of nirmatrelvir-ritonavir compared with other antiviral drugs and the impact of different antiviral drugs on the short- and long-term effects of COVID-19. The results showed that nirmatrelvir-ritonavir can reduce the mortality and hospitalization of COVID-19 patients compared with other antiviral drugs, with little difference in safety compared to the control group.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Article
Oncology
Francisco Aya, Mariana Benegas, Nuria Vinolas, Roxana Reyes, Ivan Vollmer, Ainara Arcocha, Marcelo Sanchez, Noemi Reguart
Summary: The study aimed to explore the capacity of Perfusion-Computed Tomography (pCT) in detecting early changes in tumor vascularization in non-small cell lung cancer (NSCLC) patients treated with antiangiogenic therapy, confirming the feasibility of pCT in capturing early changes in tumor vasculature and suggesting the potential of blood volume (BV) in identifying differential tumor responses to antiangiogenic therapy at an early stage.
Article
Medicine, Research & Experimental
Ruijian Li, Weiyi Li, Fang Zhang, Shanshan Li
Summary: A meta-analysis of two randomized controlled trials (RCTs) showed that the combination of bevacizumab and erlotinib can significantly prolong progression-free survival (PFS) but not overall survival (OS) in advanced EGFR-mutant non-small cell lung cancer patients. However, for patients with brain metastasis at baseline, the combination therapy demonstrated better PFS and a tendency to prolong OS.
EUROPEAN JOURNAL OF MEDICAL RESEARCH
(2023)
Review
Gastroenterology & Hepatology
Pablo A. Olivera, Juan S. Lasa, Ignacio Zubiaurre, Vipul Jairath, Maria T. Abreu, David T. Rubin, Walter Reinisch, Fernando Magro, Jean-Francois Rahier, Silvio Danese, Christian Rabaud, Laurent Peyrin-Biroulet
Summary: This study aimed to provide an update on the incidence of opportunistic infections (OIs) among adult IBD patients in randomized controlled trials (RCTs) of approved biologics and small-molecule drugs (SMDs). The study also aimed to describe the OI definitions utilized in RCTs and propose a standardized definition. The results showed that the different mechanisms of action may have specific OI profiles, and the lack of a uniform OI definition makes the estimates less reliable.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Oncology
Butuo Li, Linlin Yang, Chao Jiang, Yueyuan Yao, Haoqian Li, Shuping Cheng, Bing Zou, Bingjie Fan, Linlin Wang
Summary: This study developed a deep learning model to provide individual assessment of survival in advanced non-small cell lung cancer patients receiving bevacizumab. The integration of clinicopathologic, inflammatory, and radiomics features representation based on the DeepSurv model exhibited superior predictive accuracy.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Martin Svaton, Jiri Blazek, Gabriela Krakorova, Marcela Buresova, Zuzana Teufelova, Josef Vodicka, Karolina Hurdalkova, Magda Barinova, Milos Pesek
Summary: This study identified that in patients with non-small cell lung cancer, having laboratory markers CRP, albumin, hemoglobin, and NLR within normal ranges was associated with better disease control. Additionally, LDH and sodium were suggested as possible prognostic markers for bevacizumab treatment in combination with chemotherapy in NSCLC.
Review
Health Care Sciences & Services
Mariana Gonzalez-Morelos, Lorenzo Franco-de la Torre, Diana Laura Franco-Gonzalez, Eduardo Gomez-Sanchez, Angel Josabad Alonso-Castro, Nelly Molina-Frechero, Luis Miguel Anaya-Esparza, Mario Alberto Isiordia-Espinoza
Summary: This systematic review and meta-analysis evaluated the efficacy of methylprednisolone compared to other drugs in controlling postoperative complications following third molar surgery. Qualitative analysis showed that methylprednisolone was more effective than NSAIDs, but inferior to dexamethasone. Quantitative analysis showed no statistical difference in pain control, but a significant difference in trismus evaluation in favor of methylprednisolone on the 7th postoperative day.
Article
Immunology
Guo -Fu Lin, Yuan Xu, Hai Lin, Dong-Yong Yang, Lin Chen, Lin -Lin Huang, Xiao-Shan Su, Ying-Xuan Xu, Yi -Ming Zeng
Summary: A systematic review and meta-analysis on 16 randomized controlled trials revealed that the incidence and risk of CIP in NSCLC patients were higher with ICIs compared to chemotherapy. Combination therapy of ICIs with chemotherapy showed a higher incidence of CIP and higher mortality rate compared to monotherapy. Early detection, proper administration, and optimal management are crucial in preventing potential CIP deterioration.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Review
Oncology
Jiawei Zhou, Jianling Bai, Yuanping Yue, Xin Chen, Theis Lange, Dongfang You, Yang Zhao
Summary: This meta-analysis investigated the relationship between serum potassium levels and the treatment effects of EGFR antagonists in advanced non-small cell lung cancer. The results showed a positive association between serum potassium levels and treatment efficacy, highlighting the need for considering different potassium levels in future clinical trials.
FRONTIERS IN ONCOLOGY
(2022)
Article
Pharmacology & Pharmacy
Xinyi Xu, Shengzhao Zhang, Ting Xu, Mei Zhan, Chen Chen, Chenyu Zhang
Summary: This study systematically summarized the efficacy and safety of bevacizumab biosimilars in patients with advanced non-small cell lung cancer and metastatic colorectal cancer. Pairwise meta-analysis and Bayesian network meta-analysis showed no significant difference in efficacy and safety between bevacizumab biosimilars and reference biologics, as well as among different treatment regimens. However, the certainty of the evidence was assessed as low.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Ha Yeong Choi, Ji-Eun Chang
Summary: The development of targeted therapies has revolutionized cancer treatment, offering improved efficacy with reduced side effects. This review focuses on targeted therapy in lung cancer, colorectal cancer, and prostate cancer, highlighting key molecular targets and FDA-approved drugs. Mutations in EGFR and ALK genes are significant targets in lung cancer, with drugs like osimertinib and crizotinib inhibiting these pathways. For colorectal cancer, targeting VEGF and EGFR with drugs like bevacizumab and cetuximab significantly improves outcomes. AR targeting with drugs like enzalutamide, apalutamide, and darolutamide is pivotal in prostate cancer. The review also discusses promising targets like MET, ROS1, BRAF, and PARP, along with ongoing clinical trials.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Maria Carmela Piccirillo, Laura Bonanno, Marina Chiara Garassino, Giovanna Esposito, Claudio Dazzi, Luigi Cavanna, Marco Angelo Burgio, Francesco Rosetti, Simona Rizzato, Floriana Morgillo, Saverio Cinieri, Antonello Veccia, Maximilan Papi, Giuseppe Tonini, Vittorio Gebbia, Serena Ricciardi, Daniele Pozzessere, Alessandra Ferro, Claudia Proto, Raffaele Costanzo, Manolo D'Arcangelo, Manuela Proietto, Piera Gargiulo, Raimondo Di Liello, Laura Arenare, Filippo De Marinis, Lucio Crino, Fortunato Ciardiello, Nicola Normanno, Ciro Gallo, Francesco Perrone, Cesare Gridelli, Alessandro Morabito
Summary: This study investigated the efficacy of adding bevacizumab to erlotinib as a treatment for EGFR-mutated NSCLC. The results showed that the combination therapy prolonged progression-free survival, but also increased toxicity.
JOURNAL OF THORACIC ONCOLOGY
(2022)